Abstract
The complement-dependent cytotoxic crossmatch is an informative test that detects alloantibodies in pre- and post-transplant patients, which may dictate clinical management of transplant patients. While challenging to perform, the cytotoxic crossmatch represents the only assay that provides direct evidence for the presence of potentially pathologic (i.e., cytotoxic) alloantibodies. The cytotoxic crossmatch combines patient (recipient) serum and donor cells. If donor-reactive alloantibodies are present in patient serum, these antibodies can bind donor cells. Antibody-antigen complexes, in turn, can activate the complement cascade, leading to complement-mediated cytotoxicity. Two commonly performed cytotoxic crossmatches, using donor lymphocytes as target cells, are described.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Bray RA, Nickerson PW, Kerman RH et al (2004) Evolution of HLA antibody detection: technology emulating biology. Immunol Res 29(1–3):41–54
Patel R, Terasaki PI (1969) Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280(14):735–739
Rodey GE (2000) HLA beyond tears—introduction to human histocompatibility, 2nd edn. De Novo, Inc., Durango, CO
Hopkins KA (2010) The basic lymphocyte and microcytotoxicity tests: standard and AHG enhancement. In: Hahn AB, Land GA, Strothman RA (eds) ASHI laboratory manual. American Society for Histocompatibility and Immunogenetics, Laurel, NJ
Pidwell DJ (2010) Interpretation of crossmatch results. In: Hahn AB, Land GA, Strothman RA (eds) ASHI laboratory manual. American Society for Histocompatibility and Immunogenetics, Laurel, NJ
Zachary AA, Klingman L, Thorne N et al (1995) Variations of the lymphocytotoxicity test. An evaluation of sensitivity and specificity. Transplantation 60(5):498–503
Fleisher T (2008) Laboratory reference values, in clinical immunology—principles and practice. In: RIch R et al (eds) Mosby Elsevier, Philadelphia, p 1513
Ting A, Hasegawa T, Ferrone S et al (1973) Presensitization detected by sensitive crossmatch tests. Transplant Proc 5(1):813–817
dos Reis AP, Betuel H, Reisner EG et al (1973) The utilization of antiglobulin reagents in cytotoxicity testing for HL-A. Transplantation 15(1):36–41
Fuller TC, Phelan D, Gebel HM et al (1982) Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test. Transplantation 34(1):24–29
Mariuzza RA, Phillips SE, Poljak RJ (1987) The structural basis of antigen-antibody recognition. Annu Rev Biophys Biophys Chem 16:139–159
Akkoc N, Scornik JC (1991) Intramolecular specificity of anti-HLA alloantibodies. Hum Immunol 30(2):91–98
Taylor CJ, Chapman JR, Ting A et al (1989) Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome. Transplantation 48(6):953–958
Cross DE, Greiner R, Whittier FC (1976) Importance of the autocontrol crossmatch in human renal transplantation. Transplantation 21(4):307–311
Scornik JC, Bray RA, Pollack MS et al (1997) Multicenter evaluation of the flow cytometry T-cell crossmatch: results from the American society of histocompatibility and immunogenetics-college of American pathologists proficiency testing program. Transplantation 63(10):1440–1445
Karpinski M, Rush D, Jeffery J et al (2001) Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 12(12):2807–2814
Gebel HM, Bray RA (2000) Sensitization and sensitivity: defining the unsensitized patient. Transplantation 69(7):1370–1374
Mahoney RJ, Ault KA, Given SR et al (1990) The flow cytometric crossmatch and early renal transplant loss. Transplantation 49(3):527–535
Scornik JC, Clapp W, Patton PR et al (2001) Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive. Transplantation 71(8):1098–1102
Kerman RH, Susskind B, Buyse I et al (1999) Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation 68(12):1855–1858
Gebel HM, Bray RA, Nickerson P (2003) Pre-transplant assessment of donor-reactive. HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 3(12):1488–1500
Wen R, Wu V, Dmitrienko S et al (2006) Biomarkers in transplantation: prospective, blinded measurement of predictive value for the flow cytometry crossmatch after negative antiglobulin crossmatch in kidney transplantation. Kidney Int 70(8):1474–1481
Christiaans MH, Overhof R, ten Haaft A et al (1996) No advantage of flow cytometry crossmatch over complement-dependent cytotoxicity in immunologically well-documented renal allograft recipients. Transplantation 62(9):1341–1347
Zeevi A, Girnita A, Duquesnoy R (2007) HLA antibody analysis: sensitivity, specificity, and clinical significance in solid organ transplantation. Immunol Res 36(1–3):255–264
Colombo MB, Haworth SE, Poli F et al (2007) Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine. Cytometry B Clin Cytom 72(6):465–471
Warner P (2009) Nebulous humors: defining alloantibodies in the 21st century. Hum Immunol 70(8):623–626
Aubert V, Venetz JP, Pantaleo G et al (2009) Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 70(8):580–583
Poli F, Benazzi E, Innocente A et al (2011) Heart transplantation with donor-specific antibodies directed toward denatured HLA-A*02:01: a case report. Hum Immunol 72(11):1045–1048
Opelz G, Claas FH (2009) Which human leukocyte antigen antibodies are really clinically relevant? Hum Immunol 70(8):561–562
Okuno T, Kondelis N (1978) Evaluation of dithiothreitol (DTT) for inactivation of IgM antibodies. J Clin Pathol 31(12):1152–1155
Wohler JE, Barnum SR (2009) Nylon wool purification alters the activation of T cells. Mol Immunol 46(5):1007–1010
Amos DB, Bashir H, Boyle W et al (1969) A simple micro cytotoxicity test. Transplantation 7(3):220–223
Rodey G, Bollig B, Oldfather J et al (1987) Extra reactivities detected in flow-cytometry-positive, CDC-negative crossmatches are definable HLA specificities. Transplant Proc 19(1 Pt 1):778–779
Quintanilla-Martinez L, Preffer F, Rubin D et al (1994) CD20+ T-cell lymphoma. Neoplastic transformation of a normal T-cell subset. Am J Clin Pathol 102(4):483–489
Nagakura S, Nakakuma H, Horikawa K et al (1993) Expression of decay-accelerating factor and CD59 in lymphocyte subsets of healthy individuals and paroxysmal nocturnal hemoglobinuria patients. Am J Hematol 43(1):14–18
Cui W, Fan Y, Yang M et al (2004) Expression of CD59 on lymphocyte and the subsets and its potential clinical application for paroxysmal nocturnal hemoglobinuria diagnosis. Clin Lab Haematol 26(2):95–100
Pellegrino MA, Belvedere M, Pellegrino AG et al (1978) B peripheral lymphocytes express more HLA antigens than T peripheral lymphocytes. Transplantation 25(2):93–95
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Peña, J.R., Fitzpatrick, D., Saidman, S.L. (2013). Complement-Dependent Cytotoxicity Crossmatch. In: Zachary, A., Leffell, M. (eds) Transplantation Immunology. Methods in Molecular Biology, vol 1034. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-493-7_13
Download citation
DOI: https://doi.org/10.1007/978-1-62703-493-7_13
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-492-0
Online ISBN: 978-1-62703-493-7
eBook Packages: Springer Protocols